Alivus Life Sciences P/E Ratio
Current P/E Ratio
26.65
High Valuation
High - Growth expectations or overvalued
Alivus Life Sciences P/E ratio. Alivus Life Sciences (ALIVUS) P/E ratio is 26.65 (High), EPS (TTM) ₹45.99, current price ₹1250.60 on NSE — High - Growth expectations or overvalued. Also explore ALIVUS stock price history to track price trends across different timeframes.
Current Valuation Metrics
P/E Ratio
26.65
Current Price
₹1250.60
EPS (TTM)
₹45.99
Exchange
NSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
54.9
Sector Median
32.01
Sector Rank
#11 of 200
Sector Percentile
5.5%
ALIVUS P/E Ratio — Valuation Signal & Historical Context
Alivus Life Sciences P/E 26.65 — signal: Overvalued. For live price, revenue and the complete fundamental profile, see ALIVUS share price.
- Stock appears overvalued with PE of 26.65, suggesting caution for new investments
- Trading at discount to sector average PE of 54.9
ALIVUS vs Healthcare Peers — P/E Ratio Comparison
Alivus Life Sciences P/E 26.65 vs Healthcare average 54.9, median 32.01 — range 2.02–722.21.
Sector Average
54.9
Sector Median
32.01
Lowest P/E
2.02
Highest P/E
722.21
Companies
200
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.02 | ₹60 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.33 | ₹55 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.86 | ₹6,006 | Low |
| Dipna Pharmachem | DPL | 3.97 | ₹11 | Low |
| JFL Life Sciences | JFLLIFE | 5.05 | ₹65 | Low |
| Royal Sense | ROYAL | 5.39 | ₹40 | Low |
| Kabra Drugs | KABRADG | 5.47 | ₹41 | Low |
| GKB Ophthalmics | GKB | 5.85 | ₹32 | Low |
| Colinz Laboratories | COLINZ | 6.31 | ₹18 | Low |